Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.
Tibotec, Inc · HIV
Phase 3
Completed
10
2013-07
Industry sponsor intelligence
Tibotec, IncClinical Pipeline.
Lead-sponsor view of Tibotec, Inc's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 1
- Recruiting
- 0
- Active
- 0
- Completed
- 1
- Results posted
- 1
- Avg enrollment
- 10
Pipeline overview
Programs by phase and activity.
Velocity
Tibotec, Inc trials by start year
Study start year · indexed snapshot
Development
Trials by phase
1phase labels
Early Phase 10
Phase 10
Phase 20
Phase 31
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Enfuvirtide → | 1 | 0 | 0 | 1 | 0 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Search sponsor records
All Tibotec, Inc studies.
This page groups studies where Tibotec, Inc is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
1 matching study
Last registry update first